The BrainWave - Episode 6

Welcome to Episode 6 edition of?#TheBrainWave .?

Your Neurology Newsletter brought to you by?Ryan Tosh ?and?#CMMedical .

Did we miss something big that happened at your company? Leave us a comment or a message to let us know.

Financial News:

DiaMedica Therapeutics Inc. announces closing of their $37.5 Million Private Placement to accredit investors.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke.?

Assure Neuromonitoring have signed a letter of intent to purchase certain assets of INNOVATION NEUROMONITORING, LLC

This is going to be a great opportunity for Assure to expand their business further within Texas and ensures their entry into the South Carolina market! Congratulations John Farlinger and the wider Assure Neuromonitoring team!

Alongside this recent purchase, Assure have expanded their service offerings to address the high growth EEG services market. Assure has the exclusive rights to offer Neurovative Diagnostics comprehensive suite of EEG services to Assure's current and future hospitals.

What a great month Assure have had! What's next?

Carthera has just announced a successful € 37.5m Series B round to launch the pivotal trial for recurrent glioblastoma and continue developing additional indications.

“We are delighted with the outcome of our Series B funding round. The company is now in a strong position to launch an ambitious phase 3 trial and pursue the evaluation of its SonoCloud technology in multiple clinical indications,” said? Frédéric Sottilini , CEO of Carthera. “In the next few years we are aiming at first market approval for our SonoCloud-9 device for the treatment of recurrent glioblastoma and we are eager to pursue the development of our proprietary platform technology in other brain diseases with significant unmet needs.”

Congratulations to Frederic and the wider Carthera team!

Vertos Medical announced it has raised $26 million in an oversubscribed Series C equity funding round. The financing was lead by new investor Norwest Venture Partners alongside participation from existing investors including Pitango .

Eric Wichems is delighted to have Norwest join their existing and growing investor group, saying: “With their support, we are confident in our ability to accelerate our commercial expansion and achieve our goal of making the Mild Procedure accessible to every patient suffering from lumbar spinal stenosis (LSS) in the United States.”

Clinical News:

Nervonik, Inc. have introduced its first miniaturized wireless battery-less #neuromodulation technology, designed specifically for preclinical research. The innovative implant offers unparalleled versatility, suitable for deployment in both and chronic animal models.

Applications include peripheral nerve stimulation (PNS), spinal cord stimulation (SCS), hypoglossal nerve?stimulation (HNS), sacral neuro-modulation (SCS), vagus nerve stimulation(VNS), custom electrode testing, and more.

Congratulations Barry Keenan and the wider Nervonik team on this release.

Tivic Health ClearUP expands target market offering to include individuals who are sleep deprived, medication restricted and athletes.

A recent Tivic study with over 2,000 representative consumers conducted by Intellego Insights highlights patterns of the large unmet market. The results of the study involved consumers over the age of 18 experiencing inflammation-related symptoms related to allergies, congestion, head pain, and sinus issues. Of the consumers that participated in the study:

• 94% of these consumers use medication to treat their symptoms. However, 58% of these try to avoid medication, if at all possible.
• 91% of these consumers have sleep issues, such as trouble sleeping and waking up often, snoring, and obstructive sleep apnea.
• 69% of these consumers experience exercise-related nasal issues, such as post-nasal drip after exercise or running, and are unable to breathe comfortably through their nose during exercise or exertion.

Cala Health launches the Cala klQ System, offering meaningful tremor relief for patients with Essential Tremor and now #parkinson disease.

The Cala kIQ System delivers Cala TAPS (Transcutaneous Afferent Patterned Stimulation) therapy, which is validated by large clinical studies and real-world evidence demonstrating clinically meaningful tremor reduction and improvement in activities of daily living (ADLs).

“At Cala, we’ve always been committed to expanding patient access and accelerating innovation in TAPS therapy for indications beyond essential tremor,” said Renee Ryan , CEO at Cala. “By expanding into Parkinson’s disease, we are now able to bring this powerful treatment to additional patients who suffer from action hand tremors.”

Congratulations on this launch Cala Health, I'm also loving the new logo!

FDA Approvals:

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) seeks 510k clearance from FDA for its first therapeutic device, the OneRFAblation System.

CEO Dave Rosa said “This is a monumental day for NeuroOne as it represents the first known FDA 510(k) submission of an sEEG electrode intended to record brain activity and also be used as an RF probe to ablate nervous tissue.

“In addition, it marks the company’s first complete system combining hardware, software and our novel electrode technology.

“Over the past few years, we have been excited with the feedback we have received from our advisory board as well as the performance of the system in animal feasibility studies.”

NeuroOne expects to receive initial feedback from the FDA by 7 August this year.

Sensome and ASAHI INTECC CO., LTD. - Medical Division announced a collaboration to develop the next generation of Clotild smart guidewire, with Asahi Intecc taking on the manufacturing role for its #AI powered device intended for treatment of acute ischaemic stroke.

The Clotild smart guidewire—which incorporates Sensome’s AI-powered tissue microsensor—aims to change this statistic. The device has the potential to provide physicians with critical information about clot features, enabling them to make more informed decisions during the procedure.

Congratulations on this recent collaboration Franz Bozsak and Masahiko Miyata

Neuro-Spotlight

A new section of #TheBrainWave - here I'll be highlighting certain companies and their technology and teams behind them, following conversations with their senior leadership team.

This week... lets talk about uCat .

A number of companies within the BCI space are currently focussing on the implantable and the clinical data coming from their patients, but once the data has been decoded and the intention to move or talk has been identified what do you do with that data?

How can we support patients even further?

This is where Sam Hosovsky and his team at uCat come in.

uCat combines VR & AI to create an accessible Metaverse for all. uCat is here to help the first paralyzed users feel independent insight the Meteverse - equal expression and participation for everyone to meet without limitations.

uCat allows the user to develop, create and use their own avatar so they can interact with family and friends in the Metaverse. Like the avatar below;

Sam and I had a great conversation recently - discussing the why and the need behind uCat. It's fantastic to see another patient centric team looking to better patients lives through the technology we currently have on offer.

Keep an eye out for uCat later this year and 2024. Exciting news is coming...

Check out their website - https://www.ucat.app/

Recent Hires:

Kandu Health? have appointed a new CEO, and also enrols first 50 patients in stroke recovery programme.

Kirsten Carroll has been appointed the new CEO of Kandu Health - Kandu are a digital health start-up with the aim of improving quality of life for people affected by stroke.

Alongside this Kandu have appointed CFO - Stefan Heuser and Senior VP of Commercialization Clayton Duncan

A team that I can't wait to hear more about! Congratulations Kandu on these new appointments.

Lets talk about Nevro . If you haven't seen the exciting news recently then this will be an exclusive for you.

Nevro have announced the recent appointment of a new CCO.

Welcome Greg Siller - Greg is an accomplished commercial leader with significant senior management experience working for the likes of Stryker for 17 years. Having recently served as VP & General Manager of the Stryker Interventional Spine business, he is a great addition to the senior leadership team at Nevro. Congratulations on the new role Greg!

SetPoint Medical appoints Rohan Seth as their Chief Financial Officer with over 20 years experience managing finance and accounting functions.

Murthy Simhambhatla - President and CEO said: “Rohan's proven track record of success in managing finance and business development functions will be instrumental as we continue to advance our therapeutic platform through clinical development.”

Searching for a new role? Looking to grow your current team?

Get in touch or send me a direct message:

??Email:?[email protected]

??Contact Number: +44 07814914608